MECLIZINE Drug Patent Profile
✉ Email this page to a colleague
When do Meclizine patents expire, and what generic alternatives are available?
Meclizine is a drug marketed by Invagen Pharms, Ivax Sub Teva Pharms, Nexgen Pharma Inc, Pliva, Abc Holding, Amneal Pharms, Anabolic, Ani Pharms, Aurobindo Pharma Usa, Bundy, Chartwell Rx, Epic Pharma Llc, Heritage, Jubilant Cadista, Kv Pharm, Rising, Sandoz, Sciegen Pharms, Senores Pharms, Strides Pharma Intl, Superpharm, UDL, Vangard, Watson Labs, and Zydus Lifesciences. and is included in thirty-seven NDAs.
The generic ingredient in MECLIZINE is meclizine hydrochloride. There are seventeen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the meclizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Meclizine
A generic version of MECLIZINE was approved as meclizine hydrochloride by ZYDUS LIFESCIENCES on June 23rd, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MECLIZINE?
- What are the global sales for MECLIZINE?
- What is Average Wholesale Price for MECLIZINE?
Summary for MECLIZINE
| US Patents: | 0 |
| Applicants: | 25 |
| NDAs: | 37 |
| Drug Prices: | Drug price information for MECLIZINE |
| Drug Sales Revenues: | Drug sales revenues for MECLIZINE |
| DailyMed Link: | MECLIZINE at DailyMed |



